Aarti Pharmalabs share news, announcements and annual reports
NSE: AARTIPHARMBSE: 543748Pharmaceuticals & BiotechnologySmall Cap
Aarti Pharmalabs Limited · Face value ₹5 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jan 2023
Last close ₹872.70down ₹54.95 (5.92%)BSE ₹873.65
Share price at the NSE close on 30 Oct 2026. Previous close ₹927.65.
30 Oct: open ₹938.00, high ₹938.00, low ₹865.00
52-week range of traded prices to 30 Oct 2026
₹585.00Low, 30 Mar 2026₹1,002.40High, 30 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹7,914 Cr705th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.51
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.40%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 11.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.37
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 6,43,47839.8% delivered
Aarti Pharmalabs disputes and clarifications
13 filed, newest first.
Jan 2026
12 Jan · Legal
The exchange asked on 9 Jan 2026
Oct 2025
Sep 2025
8 Sep · Legal
Exchange has sought clarification from Aarti Pharmalabs Limited for the quarter ended 30-Jun-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted in XBRL with discrepancies The response of the Company is awaited.
Jan 2025
18 Jan · Legal
3 Jan · Legal
Jul 2024
14 Jul · Legal
Exchange has sought clarification from Aarti Pharmalabs Limited with respect to announcement dated 13-May-2024, regarding Appointment of Mrs Nehal Garewal as Non- Executive Director of the company w.e.f. May 13, 2024.". On basis of above the Company is required to clarify following: 1. Affirmation that the Director being appointed is not debarred from holding the office of director by virtue of any SEBI order or any other such authority. The response of the Company is awaited.
Jun 2024
10 Jun · Legal
Exchange has sought clarification from Aarti Pharmalabs Limited for the quarter ended 31-Mar-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
May 2023
23 May · Legal
Exchange has sought clarification from Aarti Pharmalabs Limited for the quarter ended 31-Mar-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.
Apr 2023
18 Apr · Legal
Significant movement in price has been observed in Aarti Pharmalabs Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.